Department of Radiation Oncology, groupe Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, 47-83, boulevard de l'Hôpital, 75013, Paris, France.
Department of Head and Neck Surgery, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.
Curr Oncol Rep. 2019 Nov 14;21(11):102. doi: 10.1007/s11912-019-0856-5.
Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm.
With the rise of novel therapeutic techniques and medications, many treatment options for both locoregional and distant metastatic disease have become available. The evolving paradigm of metastatic disease now integrates the concept of oligometastatic disease. On top of systemic treatments, patients with low metastatic burden can benefit from curative approaches such as local therapies (surgery, radiotherapy) directed to either primary tumour and distant metastasis. However, data integrating these considerations in the management of metastatic HNSCC is still lacking. Based on this algorithm, we can provide a tailored treatment to each patient with synchronous metastatic HNSCC, according to their age, general condition and metastatic burden.
转移性头颈部鳞状细胞癌（HNSCC）的治疗具有挑战性。本文分析了同步转移性 HNSCC 患者的当前治疗选择，并提出了治疗方案。
随着新的治疗技术和药物的出现，局部和远处转移性疾病的许多治疗选择已经出现。转移性疾病的不断发展的模式现在整合了寡转移疾病的概念。除了全身治疗外，转移负担较低的患者还可以从针对原发肿瘤和远处转移的局部治疗（手术、放疗）中获益。然而，在转移性 HNSCC 的管理中整合这些考虑因素的数据仍然缺乏。基于该方案，我们可以根据每个同步转移性 HNSCC 患者的年龄、一般状况和转移负担，为他们提供量身定制的治疗。
